Please use this identifier to cite or link to this item:
Title: Cost-minimization analysis of oral versus intravenous antibiotic treatment for <i>Klebsiella pneumoniae</i> liver abscess
Authors: Yoong, Joanne 
Yuen, Kah Hung 
Molton, James S 
Ding, Ying 
Cher, Boon Piang 
Chan, Monica
Kalimuddin, Shirin 
Oon, Jolene 
Young, Barnaby
Low, Jenny 
Salada, Brenda MA
Lee, Tau Hong
Wijaya, Li Min
Fisher, Dale 
Izharuddin, Ezlyn
Wei, Yuan 
Phillips, Rachel 
Moorakonda, Rajesh 
Lye, David C 
Archuleta, Sophia 
Keywords: Science & Technology
Multidisciplinary Sciences
Science & Technology - Other Topics
Issue Date: 16-Jun-2023
Citation: Yoong, Joanne, Yuen, Kah Hung, Molton, James S, Ding, Ying, Cher, Boon Piang, Chan, Monica, Kalimuddin, Shirin, Oon, Jolene, Young, Barnaby, Low, Jenny, Salada, Brenda MA, Lee, Tau Hong, Wijaya, Li Min, Fisher, Dale, Izharuddin, Ezlyn, Wei, Yuan, Phillips, Rachel, Moorakonda, Rajesh, Lye, David C, Archuleta, Sophia (2023-06-16). Cost-minimization analysis of oral versus intravenous antibiotic treatment for Klebsiella pneumoniae liver abscess. SCIENTIFIC REPORTS 13 (1). ScholarBank@NUS Repository.
Abstract: A cost-minimization analysis was conducted for Klebsiella pneumoniae liver abscess (KLA) patients enrolled in a randomized controlled trial which found oral ciprofloxacin to be non-inferior to intravenous (IV) ceftriaxone in terms of clinical outcomes. Healthcare service utilization and cost data were obtained from medical records and estimated from self-reported patient surveys in a non-inferiority trial of oral ciprofloxacin versus IV ceftriaxone administered to 152 hospitalized adults with KLA in Singapore between November 2013 and October 2017. Total costs were evaluated by category and payer, and compared between oral and IV antibiotic groups over the trial period of 12 weeks. Among the subset of 139 patients for whom cost data were collected, average total cost over 12 weeks was $16,378 (95% CI, $14,620–$18,136) for the oral ciprofloxacin group and $20,569 (95% CI, $18,296–$22,842) for the IV ceftriaxone group, largely driven by lower average outpatient costs, as the average number of outpatient visits was halved for the oral ciprofloxacin group. There were no other statistically significant differences, either in inpatient costs or in other informal healthcare costs. Oral ciprofloxacin is less costly than IV ceftriaxone in the treatment of Klebsiella liver abscess, largely driven by reduced outpatient service costs. Trial registration: Identifier NCT01723150 (7/11/2012).
ISSN: 2045-2322
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Cost-minimization analysis of oral versus intravenous antibiotic treatment for Klebsiella pneumoniae liver abscess.pdfPublished version956.08 kBAdobe PDF



Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.